Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Werewolf Therapeutics, Inc. - Common Stock (NQ:HOWL)

0.8433 -0.0267 (-3.07%)
Streaming Delayed Price Updated: 2:25 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Werewolf Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Where Werewolf Therapeutics Stands With Analysts
Via Benzinga
Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know
Via Benzinga
The Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 Experts
Via Benzinga
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Beats Revenue for Q2 2024
HOWL stock results show that Werewolf Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Misses Revenue for Q1 2024
HOWL stock results show that Werewolf Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel... 
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023
HOWL stock results show that Werewolf Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.